tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gaynor JJ and Ciancio G The Importance of Using Serially Measured Tacrolimus Clearance Values, Especially During the Early Posttransplantation Period. 2018 Transplantation pmid:29271869
Peterson LB et al. A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. 1998 Transplantation pmid:9448137
Silva HT et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. 2014 Transplantation pmid:24521771
Dresske B et al. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation. 2003 Transplantation pmid:12717217
Eason JD et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. 2003 Transplantation pmid:12717237
Cendales LC et al. Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. 2005 Transplantation pmid:16340790
Mañez R et al. Fluconazole therapy in transplant recipients receiving FK506. 1994 Transplantation pmid:7515201
Sakr M et al. Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients. 1992 Transplantation pmid:1373535
Hirano Y et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. 1992 Transplantation pmid:1373536
Pescovitz MD et al. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. 2009 Transplantation pmid:19855247
Drachenberg CB et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. 1999 Transplantation pmid:10459544
Stegall MD et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. 1997 Transplantation pmid:9422404
Deuse T et al. The interaction between FK778 and tacrolimus in the prevention of rat cardiac allograft rejection is dose dependent. 2004 Transplantation pmid:15084926
Ferraris JR et al. Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection: changes in the immune responses. 2004 Transplantation pmid:15084930
Shapiro R et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. 1999 Transplantation pmid:10628763
Gerlach UA et al. Intragraft and Systemic Immune Parameters Discriminating Between Rejection and Long-Term Graft Function in a Preclinical Model of Intestinal Transplantation. 2017 Transplantation pmid:27607529
Oz HS et al. Provocative effects of the immunosuppressants rapamycin, tacrolimus, and dexamethasone on pneumonitis in contrast to the anti- pneumonitis effects of mycophenolate mofetil. 2001 Transplantation pmid:11685124
Staatz CE et al. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. 2001 Transplantation pmid:11579300
Selzner N et al. Conversion from cyclosporine to FK506 in adult liver transplant recipients: a combined North American and European experience. 2001 Transplantation pmid:11579301
Petruzzo P et al. The International Registry on Hand and Composite Tissue Transplantation. 2010 Transplantation pmid:21052038
Rostaing L et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. 2005 Transplantation pmid:15818323
Grudé P et al. MDR1 gene expression in peripheral blood mononuclear cells after liver transplantation. 2002 Transplantation pmid:12085008
Jin S et al. Effect of tacrolimus on the expression of macrophage scavenger and nuclear hormone receptors in THP-1-derived human macrophages. 2004 Transplantation pmid:15114099
Straatman LP and Coles JG Pediatric utilization of rapamycin for severe cardiac allograft rejection. 2000 Transplantation pmid:10949201
Burke GW et al. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement. 1999 Transplantation pmid:10573073
Ahuja M et al. Polyoma virus infection after renal transplantation. Use of immunostaining as a guide to diagnosis. 2001 Transplantation pmid:11349723
Pérgola PE et al. Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. 2001 Transplantation pmid:11349738
Sanchez EQ et al. Predicting renal failure after liver transplantation from measured glomerular filtration rate: review of up to 15 years of follow-up. 2010 Transplantation pmid:20098288
Piao SG et al. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. 2014 Transplantation pmid:24825522
Gujadhur A et al. CMV sinusitis in a HIV-negative renal transplant recipient. 2014 Transplantation pmid:24827770
Moffatt SD et al. STAT 6 up-regulation by FK506 in the presence of interleukin-4. 2000 Transplantation pmid:10798785
Riegersperger M et al. Effect of conversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients. 2013 Transplantation pmid:23594858
Miyazawa H et al. Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition. 1995 Transplantation pmid:7537396
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Josephson MA et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. 2006 Transplantation pmid:16534472
Homma M et al. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. 2002 Transplantation pmid:11821750
Zaltzman JS A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. 2010 Transplantation pmid:21166111
van Maarseveen EM et al. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. 2013 Transplantation pmid:23250333
Chen H et al. Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. 2000 Transplantation pmid:10836361
Gouraud A et al. Follow-up of tacrolimus breastfed babies. 2012 Transplantation pmid:22996303
Ueda M et al. A proposal of FK506 optimal dosing in living related liver transplantations. 1995 Transplantation pmid:7544035
Kim SJ et al. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients. 2006 Transplantation pmid:17038908
Vanrenterghem Y et al. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. 2004 Transplantation pmid:15257032
Bayés B et al. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. 2004 Transplantation pmid:15257035
Deuse T et al. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545. 2012 Transplantation pmid:22971540
Mathew A et al. Reversal of steroid-resistant rejection in renal allograft recipients using FK506. 1995 Transplantation pmid:7482730
Glotz D et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. 2010 Transplantation pmid:20386144
Sher LS et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. 1997 Transplantation pmid:9256184
Opelz G and Döhler B Association of mismatches for HLA-DR with incidence of posttransplant hip fracture in kidney transplant recipients. 2011 Transplantation pmid:21452411
Pascher A et al. Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation. 2003 Transplantation pmid:12923454